Why does Humira cost $72,000 a year?

Several reasons layered: legitimate R&D recovery (~$2B for the original development), complex biologic manufacturing, rebate games that distort list prices upward, and — until 2023 — lack of biosimilar competition. Biosimilars are now driving real price competition on Humira.

What is a biosimilar?

An FDA-approved biologic drug that’s highly similar to an already-approved reference biologic (like a generic for biologics). Biosimilars are typically 15-35% cheaper. For adalimumab (Humira), multiple biosimilars launched in 2023-2024.

How do I afford a specialty drug on Medicare?

The 2026 Medicare Part D out-of-pocket cap is $2,000/year. After that, you pay $0 for covered drugs. For the $0-$2,000 portion, apply for the manufacturer’s Patient Assistance Program or an independent copay foundation grant (HealthWell, PAN, Good Days, NORD).

Why can’t I use a copay card with Medicare?

Federal law (Anti-Kickback Statute) prohibits manufacturer copay assistance on drugs paid for by Medicare, Medicaid, Tricare, or VA — it’s considered an inducement. Manufacturers run Patient Assistance Programs as a legal alternative for federal-coverage patients.

Specialty drugs: why they cost $50,000+ and what to do about it

A biologic for rheumatoid arthritis (Humira) lists at $72,000/year. A cell therapy for leukemia (Kymriah) lists at $475,000 for a one-time dose. A gene therapy for spinal muscular atrophy (Zolgensma) lists at $2.1 million. The prices aren’t typos. Understanding why specialty drugs cost what they do — and what the actual patient path looks like — requires separating myth from policy.

What makes a drug “specialty”

CMS defines specialty drugs as those costing more than ~$950/month to the plan (2026 threshold, adjusted annually). They share a few technical features:

Complex manufacturing. Biologics are grown in living cell lines — not synthesized in a lab. Cell therapies customize T cells from each patient. Gene therapies involve engineered viral vectors. The production cost per dose is legitimately high.
Limited patient population. Most specialty drugs treat conditions with 10,000-500,000 US patients. The manufacturer has to recoup $1-2B of R&D across a smaller population.
Cold chain + handling. Many biologics ship refrigerated, have short shelf lives, and require specialty pharmacy distribution.

What drives the listed price

Three factors dominate:

R&D recovery. Bringing a biologic to market costs $1-2.5B including failures. The price has to recover that over patent life (~12 years from approval for biologics).
Rebate games. The sticker price ≠ what PBMs and insurers actually pay. Manufacturers quote a high list price, then give PBMs rebates of 20-60%. The rebate system distorts the list price upward.
Negotiation leverage. When Medicare couldn’t negotiate (pre-IRA) and commercial plans had weak leverage, manufacturers set prices based on what the most-desperate payer would pay.

What patients actually pay

Almost never the sticker price. The path usually looks like:

Insurance covers the bulk. Specialty drugs sit on Tier 5 with 25-33% coinsurance. On a $6,000/month biologic, that’s $1,500-$2,000 out-of-pocket before any cost-sharing help.
Manufacturer copay card drops it to $0-$10. If you have commercial insurance, the copay card is usually generous on specialty drugs — $0 copay for many programs.
If you have Medicare/Medicaid, copay cards don’t apply. You need a Patient Assistance Program (PAP) from the manufacturer or an independent copay foundation grant. See our PAP guide.
In 2026, Medicare’s $2,000 OOP cap changes everything. Previously specialty drugs could bankrupt Medicare patients; now $2,000 is the annual limit regardless of drug cost.

The access playbook

If your prescriber says “we need to start you on a specialty drug”:

Before the first prescription, find the copay card or PAP. Our drug directory links these directly. For biologics, manufacturers often have dedicated patient-support teams — use them.
If you have commercial insurance, activate the copay card before filling. Pharmacists run it as a secondary claim after insurance.
If you have Medicare, apply for the manufacturer’s PAP or check independent copay foundations (HealthWell Foundation, PAN Foundation, Good Days, NORD). Foundations typically provide disease-specific grants of $2,000-$10,000.
Enroll with a specialty pharmacy. Most specialty drugs don’t come from a retail pharmacy — they’re dispensed by specialty pharmacies like Accredo, CVS Specialty, or the manufacturer’s preferred partner. They handle refrigerated shipping, injection training, and clinical monitoring.
Budget for the first month gap. Copay card activations are fast (same-day). PAP approvals take 2-6 weeks. Bridge-supply programs are available for most specialty drugs — ask specifically.

Biosimilars: the coming disruption

Biosimilars are FDA-approved “close-enough” versions of biologics, like generics for biologics. They’re typically 15-35% cheaper. For drugs like adalimumab (Humira), multiple biosimilars launched in 2023-2024 and have steadily cut prices. If your drug has a biosimilar available, ask your prescriber whether it’s an option.

Is it getting better?

Gradually. The 2022 Inflation Reduction Act let Medicare negotiate prices on 10 drugs (expanding to 20 in 2027). The 2026 $2,000 OOP cap in Medicare Part D is the biggest single change in years for specialty-drug affordability. Biosimilar competition is increasing. But prices on net have continued rising, and for brand-new gene therapies ($1M+ doses), the affordability story is still very patient-dependent.